Drugmakers see a pricing blueprint in an $850,000 gene therapy

loading...


Drugmakers see a pricing blueprint in an 0,000 gene therapy
SAN FRANCISCO (Reuters) – Global drugmakers are looking to a tiny biotech’s $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines.


Source: Health And Fitness

Reply

Pin It on Pinterest

Shares
Share This
loading...